• English
  • Português
  • Español
  • Français
  • Deutsch
  • Русский
  • 简体中文
  • हिन्दी
  • العربية

Phenobarbital in Neonatal Abstinence Syndrome (NAS): Clinical Indications & Management Protocols

Cover page titled Phenobarbital in Neonatal Abstinence Syndrome (NAS): Clinical Indications and Management Protocols, showing a vial of Phenobarbital Sodium Injection USP 130 mg/mL beside a brain and heartbeat icon graphic on a background of scattered syringes and medication vials.

Phenobarbital in Neonatal Abstinence Syndrome (NAS)

Clinical Indications & Management Protocols

Distilled insights from the Toronto Resident’s Handbook of Neonatology

Clinical Pathway & Treatment Trigger

Infographic showing the three-step clinical pathway for NAS management from non-pharmacologic care to primary pharmacologic therapy to advanced escalation, plus a gauge diagram illustrating the modified Finnegan score thresholds that trigger treatment.

Clinical Pathway

  • Non-Pharmacologic: Skin-to-skin, rooming-in, swaddling, low-stimulation environment, breastfeeding.
  • Primary Pharmacologic: Oral Morphine (starting at 0.32 – 0.8 mg/kg/day based on Finnegan score).
  • Advanced Escalation: Phenobarbital or Clonidine. Deployed when primary mechanisms fail.

The Treatment Trigger

Modified Finnegan Score: ranges from Monitor to Treat.

  • ≥8 on 3 consecutive assessments
  • Average ≥12 on 2 consecutive assessments

Note: Scoring begins 1-2 hours post-delivery and continues q3-4h for a minimum of 72 hours. 30-75% of infants will require medical intervention.

Clinical Triggers for Escalation

Infographic listing two clinical triggers for escalating NAS treatment to phenobarbital: refractory symptoms despite high-dose first-line therapy, and complex exposure from maternal polysubstance use, with warning icons.

Clinical Triggers for Escalation

Trigger 1: Refractory Symptoms

The infant remains highly symptomatic despite receiving high-dose first-line therapy (≥0.8 mg/kg/day PO Morphine).

Trigger 2: Complex Exposure

Indicated specifically as an adjunct in cases of maternal polysubstance use, where opioid-specific withdrawal protocols are insufficient.

High-Visibility Dosing Reference (Loading)

Dosing reference chart for phenobarbital showing load, maintain, and wean phases, alongside NeoFast app screenshots demonstrating a loading dose calculation of 20mg (20 drops) for a 2kg infant.

High-Visibility Dosing Reference

  • LOAD: 10 mg/kg PO, q12h x 3 doses
  • MAINTAIN: 5 mg/kg/day PO, Daily maintenance
  • WEAN: Reduce by 10-20% of total daily dose every 1-2 days once symptoms are controlled.

NeoFast App Reference – Loading Dose Example

Medicine: Phenobarbital

Route: Oral

Formulation: 40mg/mL – 4% gtts

Mode: Loading

Weight (kg): 2

Desired dose (mg/kg/dose): 10

Suggested Loading dose: 15 to 20 mg/kg/dose. Abstinence: 16 mg/kg/dose

Dose20mg
IntervalNow
Dose20 drops

Note: in the drop presentation, 1 drop usually corresponds to 1 mg (see manufacturer’s presentation). The drops should be diluted in water. Maximum anticonvulsant dose is up to 40 mg/kg, increased every 10 mg/kg/dose for 20 to 30 min. Premature infants < 1,500 g may require Loading doses of less than 15 mg/kg, followed by a single dose of less than 3…

High-Visibility Dosing Reference (Maintenance)

NeoFast app screenshots showing maintenance dosing calculation for phenobarbital in a 2kg infant, resulting in a 5mg (5 drops) dose every 12 hours, with load and maintain reference boxes above.

High-Visibility Dosing Reference

  • LOAD: 10 mg/kg PO, q12h x 3 doses
  • MAINTAIN: 5 mg/kg/day PO, Daily maintenance

NeoFast App Reference – Maintenance Dose Example

Medicine: Phenobarbital

Route: Oral

Formulation: 40mg/mL – 4% gtts

Mode: Maintenance

Weight (kg): 2

Desired dose (mg/kg/day): 5

Suggested maintenance dose: 3 to 5 mg/kg/day. Abstinence: 2 to 8 mg/kg/day

Dose5mg
Interval12/12h
Dose5 drops

Note: in the drop presentation, 1 drop usually corresponds to 1 mg (see manufacturer’s presentation). The drops should be diluted… Maximum anticonvulsant dose is up to 40 mg/kg, increased every 10 mg/kg/dose for 20 to 30 min. Premature infants < 1,500 g may require Loading doses of less than 15 mg/kg, followed by a single dose of less than 3 mg/kg/dose 24 hours later. In the case of withdrawal syndrome, weaning can be achieved by reducing the dose by 20% every other day.

Additional information: Bibliographical references

Please note: the information presented in this application is taken from bibliographical references and is for information purposes only. The doctor is solely responsible for prescribing, administering and making the necessary adjustments. This app does not replace medical guidelines or clinical judgment.

Anatomical Warning Tag & Morphine vs. Phenobarbital Comparison

Infographic detailing pharmacokinetics, neurological, and gastrointestinal risks of phenobarbital, alongside a comparison table between morphine and phenobarbital covering role, clinical trigger, half-life, and primary cautions.

Anatomical Warning Tag

  • Pharmacokinetics: Extremely long half-life (45-100 hours). Mandates strict serum level monitoring.
  • Neurological Impact: High sedative effect. Can mask alternative neurological symptoms.
  • Gastrointestinal Risk: Formulation contains 15% alcohol. May actively worsen GI symptoms.

Morphine vs. Phenobarbital Comparison

MorphinePhenobarbital
RolePrimary First-LineSecondary Adjunct
Clinical TriggerFinnegan Score ≥8Refractory on ≥0.8 mg/kg/day Morphine or Polysubstance exposure
Half-LifeShort (easier titration)45-100 hours (prolonged wash-out)
Primary CautionsOpioid toxicitySevere sedation, 15% alcohol content, worsened GI symptoms

NAS Escalation Pyramid & NeoFast App

Pyramid diagram illustrating the three-tier NAS escalation pathway from universal non-pharmacologic care to first-line morphine to adjunct phenobarbital for complex or refractory cases, followed by the NeoFast app logo over a glowing world map with app store download buttons.

NAS Escalation Pyramid

  • Universal Care: Non-pharmacologic management (low stimulation, swaddling). Applied to 100% of at-risk infants.
  • Targeted Intervention – First-Line Morphine: Triggered strictly by Modified Finnegan Score thresholds (≥8 or ≥12).
  • Complex / Refractory – Adjunct Phenobarbital: Reserved specifically for treatment-resistant cases (max Morphine) or complex polysubstance withdrawal.

Takeaway: Phenobarbital is a potent, long-acting adjunct reserved for the peak of the NAS escalation pathway.

NeoFast

Get it on Google Play — Download on the App Store